<DOC>
	<DOCNO>NCT02898506</DOCNO>
	<brief_summary>The objective trial study whether daily treatment liraglutide improve endogenous insulin secretion , postpones progression overt Type 1 diabetes , tolerable safe subject age 10-30 year , positive multiple islet autoantibody dysglycemia .</brief_summary>
	<brief_title>Incretin-based Therapy Late Preclinical Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1030 year age positive least 2 islet autoantibody glucose intolerance dysglycemia : impaired glucose tolerance ( IGT , 2hour pgluc 7.811.0mmol/l ) , impaired fasting glucose ( IFG , fpgluc 6.16.9mmol/l ) , and/or 10 % rise HbA1c since last measurement ( 2 12 mo ago ) , and/or pgluc least 11.1mmol/l 30 , 60 90 min OGTT pregnant allergic liraglutide ingredient Victoza type 1 diabetes diabetic ketoacidosis previous treatment last three month antidiabetic medication impair liver kidney function dialysis severe heart failure severe stomach gut problem result gastroparesis , inflammatory bowel disease past current history pancreatitis serum calcitonin value normal ( &gt; 50 ng/l least 3.4pmol/l ) presence chronic metabolic , hematologic malignant disease obesity BMI least 30 pregnant female female childbearing potential use adequate contraceptive method . breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Diabetes Type 1</keyword>
	<keyword>Diabetes , Insulin-Dependent</keyword>
	<keyword>Liraglutide</keyword>
	<keyword>Preclinical Type 1 Diabetes</keyword>
	<keyword>GLP-1 Analogue</keyword>
	<keyword>Dysglycemia</keyword>
	<keyword>Prevention</keyword>
</DOC>